Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Clinical significance of RAS-MAPK pathway mutations in Acute Myeloid Leukemia: Insights from a retrospective cohort

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMoath AlbliwiEZEmily C. ZaborHAHasan Abuamsha

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows RAS-MAPK mutations influence outcomes in acute myeloid leukemia, suggesting monitoring for high-risk patients.

Key Points

  • Mutations in the RAS-MAPK pathway were common, with distinct clinicopathological presentations in AML patients.
  • KRAS mutations were linked to a twofold increase in mortality compared to wildtype over a median of 41 months.
  • Analysis utilized multivariable logistic regression and Cox proportional hazards regression to explore outcomes.
  • These findings emphasize the need for molecular profiling in risk stratification and treatment for AML patients.

Cite This Study

Albliwi et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da0ahttps://doi.org/10.1182/blood-2025-5185
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Characteristics and clinical outcomes of newly diagnosed acute myeloid leukemia with MAPK pathway mutations: A referral-center retrospective analysis.2026
  2. 2Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP2025
  3. 3<i>KRAS</i> Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With <scp>MAPK</scp> Pathway Mutations2026
  4. 4Prognostic impact of co-occurring mutations in NPM1-mutated Acute Myeloid Leukemia2025
  5. 5Next generation sequencing profiling of pediatric Acute Myeloid Leukemia reveals distinct genetic landscapes across cytogenetic subgroups2025